bpc 157 for parkinson's disease BPC-157 Benefits, Dosage & Before/After Results The Future of Supercharging Healing

Meaning the public serves as the guinea pigs

the FDA has stated it lacks sufficient information to know whether the substance would cause harm when administered to humans Evidence snapshot: The evidence base is almost entirely preclinical, decades of animal (largely rat) studies, mostly from one Croatian research group (Sikiric et al., University of Zagreb), with a single small human trial under the brand name "Bepecin" (around 2015) that did not lead to any FDA-approved use

Smart et al.s work in Nature on Thymosin Beta-4s role in endogenous cardiac progenitor cell activation following injury illustrates the breadth of Thymosin Beta-4s tissue remodeling activity [2]

Many users find this dose sufficient for significant improvement